Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

09.01.2023 | original article

Comparison of the efficacy of equivalent doses of dexamethasone, methylprednisolone, and hydrocortisone for treatment of COVID-19-related acute respiratory distress syndrome: a prospective three-arm randomized clinical trial

verfasst von: Abbas Taher, Marjan Lashkari, Fariba Keramat, Seyyed Hamid Hashemi, Ladan Sedighi, Jalal Poorolajal, Associate Professor Maryam Mehrpooya

Erschienen in: Wiener Medizinische Wochenschrift

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

This prospective controlled clinical trial aimed to compare the efficacy of methylprednisolone, dexamethasone, and hydrocortisone at equivalent doses in patients with severe COVID-19.

Methods

In total, 106 patients with mild to moderate COVID-19-related acute respiratory distress syndrome (ARDS) were randomized to receive either dexamethasone (6 mg once a day), methylprednisolone (16 mg twice a day), or hydrocortisone (50 mg thrice a day) for up to 10 days. All participants received a standard of care for COVID-19. The primary and secondary efficacy outcomes included all-cause 28-day mortality, clinical status on day 28 assessed using the World Health Organization (WHO) eight-category ordinal clinical scale, number of patients requiring mechanical ventilation and intensive care unit (ICU) care, number of ventilator-free days, length of hospital and ICU stay, change in PaO2:FiO2 ratios during the first 5 days after treatment, and incidence of serious adverse events. P-values below 0.008 based on Bonferroni’s multiple-testing correction method were considered statistically significant.

Results

According to the obtained results, there was a trend toward more favorable clinical outcomes in terms of needing mechanical ventilation and ICU care, number of ventilator-free days, change in PaO2:FiO2 ratios during the first 5 days after treatment, clinical status score at day 28, length of ICU and hospital stay, and overall 28-day mortality in patients receiving dexamethasone compared to those receiving methylprednisolone or hydrocortisone; however, likely due to the study’s small sample size, the difference between groups reached a significant level only in the case of clinical status score on day 28 (p-value = 0.003). There was no significant difference in the incidence of serious adverse events between the study groups.

Conclusion

Based on the results, severe cases of COVID-19 treated with dexamethasone might have a better clinical status at 28-day follow-up compared to methylprednisolone and hydrocortisone at an equivalent dose. Larger multicenter trials are required to confirm our findings.
Literatur
1.
Zurück zum Zitat Organization WH. COVID-19 weekly epidemiological update. 58th ed. 2021. Organization WH. COVID-19 weekly epidemiological update. 58th ed. 2021.
2.
Zurück zum Zitat Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and clinical characteristics of COVID-19. Arch Iran Med. 2020;23(4):268–71. CrossRef Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and clinical characteristics of COVID-19. Arch Iran Med. 2020;23(4):268–71. CrossRef
3.
Zurück zum Zitat Li X, Ma X. Acute respiratory failure in COVID-19: is it “typical” ARDS? Crit Care. 2020;24(1):1–5. CrossRef Li X, Ma X. Acute respiratory failure in COVID-19: is it “typical” ARDS? Crit Care. 2020;24(1):1–5. CrossRef
4.
Zurück zum Zitat Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther. 2021;6(1):1–20. Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther. 2021;6(1):1–20.
5.
Zurück zum Zitat Jafari-Oori M, Ghasemifard F, Ebadi A, Karimi L, Rahimi-Bashar F, Jamialahmadi T, Guest PC, Vahedian-Azimi A, Sahebkar A. 18 acute respiratory distress syndrome and COVID-19: a scoping review and meta-analysis. Clin Biol Mol Aspects Covid-19. 2021;1321:211. CrossRef Jafari-Oori M, Ghasemifard F, Ebadi A, Karimi L, Rahimi-Bashar F, Jamialahmadi T, Guest PC, Vahedian-Azimi A, Sahebkar A. 18 acute respiratory distress syndrome and COVID-19: a scoping review and meta-analysis. Clin Biol Mol Aspects Covid-19. 2021;1321:211. CrossRef
6.
Zurück zum Zitat Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. CrossRef Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. CrossRef
7.
Zurück zum Zitat Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9. CrossRef Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9. CrossRef
8.
Zurück zum Zitat Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O’Callaghan A, Pardos-Gea J, Quintana A, Mekinian A, Anunciacion-Llunell A, Miró-Mur F. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review. Autoimmun Rev. 2020;19(7):102569. CrossRef Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O’Callaghan A, Pardos-Gea J, Quintana A, Mekinian A, Anunciacion-Llunell A, Miró-Mur F. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review. Autoimmun Rev. 2020;19(7):102569. CrossRef
9.
Zurück zum Zitat Marmor M, Jonas A. Corticosteroids for COVID-19-Associated ARDS. Clin Pulm Med. 2020;27(6):165. CrossRef Marmor M, Jonas A. Corticosteroids for COVID-19-Associated ARDS. Clin Pulm Med. 2020;27(6):165. CrossRef
10.
Zurück zum Zitat Zhou Y, Fu X, Liu X, Huang C, Tian G, Ding C, Wu J, Lan L, Yang S. Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis. Sci Rep. 2020;10(1):1–10. Zhou Y, Fu X, Liu X, Huang C, Tian G, Ding C, Wu J, Lan L, Yang S. Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis. Sci Rep. 2020;10(1):1–10.
11.
Zurück zum Zitat Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, Thompson BT, Ancukiewicz M; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671–84. CrossRef Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, Thompson BT, Ancukiewicz M; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671–84. CrossRef
12.
Zurück zum Zitat Annane D. Corticosteroids for COVID-19. J Intensive Med. 2021;1(1):14–25. CrossRef Annane D. Corticosteroids for COVID-19. J Intensive Med. 2021;1(1):14–25. CrossRef
14.
Zurück zum Zitat Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–41. CrossRef Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–41. CrossRef
17.
Zurück zum Zitat Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V, Shahriarirad R, Erfani A, Khodamoradi Z, Saadi MHG. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021;21(1):1–8. Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V, Shahriarirad R, Erfani A, Khodamoradi Z, Saadi MHG. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021;21(1):1–8.
18.
Zurück zum Zitat Pinzón MA, Ortiz S, Holguín H, Betancur JF, Cardona Arango D, Laniado H, Arias Arias C, Muñoz B, Quiceno J, Jaramillo D. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS ONE. 2021;16(5):e252057. CrossRef Pinzón MA, Ortiz S, Holguín H, Betancur JF, Cardona Arango D, Laniado H, Arias Arias C, Muñoz B, Quiceno J, Jaramillo D. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS ONE. 2021;16(5):e252057. CrossRef
19.
Zurück zum Zitat Ko JJ, Wu C, Mehta N, Wald-Dickler N, Yang W, Qiao R. A comparison of methylprednisolone and dexamethasone in intensive care patients with COVID-19. J Intensive Care Med. 2021;36(6):673–80. CrossRef Ko JJ, Wu C, Mehta N, Wald-Dickler N, Yang W, Qiao R. A comparison of methylprednisolone and dexamethasone in intensive care patients with COVID-19. J Intensive Care Med. 2021;36(6):673–80. CrossRef
20.
Zurück zum Zitat Khiali S, Entezari-Maleki T. Therapeutic application of corticosteroids in COVID-19: a focus on optimum dose and duration of therapy. J Clin Pharmacol. 2021;61(9):1145. CrossRef Khiali S, Entezari-Maleki T. Therapeutic application of corticosteroids in COVID-19: a focus on optimum dose and duration of therapy. J Clin Pharmacol. 2021;61(9):1145. CrossRef
21.
Zurück zum Zitat Force ADT, Ranieri V, Rubenfeld G, Thompson B, Ferguson N, Caldwell E, Fan E, Camporota L, Slutsky A. Acute respiratory distress syndrome. JAMA. 2012;307(23):2526–33. Force ADT, Ranieri V, Rubenfeld G, Thompson B, Ferguson N, Caldwell E, Fan E, Camporota L, Slutsky A. Acute respiratory distress syndrome. JAMA. 2012;307(23):2526–33.
22.
Zurück zum Zitat Marshall JC, Murthy S, Diaz J, Adhikari N, Angus DC, Arabi YM, Baillie K, Bauer M, Berry S, Blackwood B. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–e7. CrossRef Marshall JC, Murthy S, Diaz J, Adhikari N, Angus DC, Arabi YM, Baillie K, Bauer M, Berry S, Blackwood B. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–e7. CrossRef
23.
Zurück zum Zitat Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M, Umberger R. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131(4):954–63. CrossRef Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M, Umberger R. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131(4):954–63. CrossRef
26.
Zurück zum Zitat Health NIo. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2020. Health NIo. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2020.
27.
Zurück zum Zitat Organization WH. Corticosteroids for COVID-19: living guidance, 2 September 2020. World Health Organization; 2020. Organization WH. Corticosteroids for COVID-19: living guidance, 2 September 2020. World Health Organization; 2020.
28.
Zurück zum Zitat Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, Avezum A, Lopes RD, Bueno FR, Silva MVA. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307–16. CrossRef Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, Avezum A, Lopes RD, Bueno FR, Silva MVA. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307–16. CrossRef
29.
Zurück zum Zitat Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, Aguilar G, Alba F, González-Higueras E, Conesa LA. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267–76. CrossRef Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, Aguilar G, Alba F, González-Higueras E, Conesa LA. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267–76. CrossRef
30.
Zurück zum Zitat Dequin P‑F, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, François B, Aubron C, Ricard J‑D, Ehrmann S. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(13):1298–306. CrossRef Dequin P‑F, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, François B, Aubron C, Ricard J‑D, Ehrmann S. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(13):1298–306. CrossRef
31.
Zurück zum Zitat Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, van Bentum-Puijk W, Berry L, Bhimani Z, Bonten M. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317–29. CrossRef Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, van Bentum-Puijk W, Berry L, Bhimani Z, Bonten M. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317–29. CrossRef
32.
Zurück zum Zitat Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, Gómez-Barquero J, Abadía-Otero J, García-Ibarbia C, Mora V, Cerezo-Hernández A, Hernández JL, López-Muñíz G. Methylprednisolone in adults hospitalized with COVID-19 pneumonia. Wien Klin Wochenschr. 2021;133(7):303–11. CrossRef Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, Gómez-Barquero J, Abadía-Otero J, García-Ibarbia C, Mora V, Cerezo-Hernández A, Hernández JL, López-Muñíz G. Methylprednisolone in adults hospitalized with COVID-19 pneumonia. Wien Klin Wochenschr. 2021;133(7):303–11. CrossRef
33.
Zurück zum Zitat Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Safe IP, Borba MGS, Netto RLA, Maciel ABS. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2021;72(9):e373–e81. CrossRef Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Safe IP, Borba MGS, Netto RLA, Maciel ABS. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2021;72(9):e373–e81. CrossRef
34.
Zurück zum Zitat Hazbun ME, Faust AC, Ortegon AL, Sheperd LA, Weinstein GL, Doebele RL, Weinmeister KD, Liddell AM, Feldman M. The combination of tocilizumab and methylprednisolone along with initial lung recruitment strategy in coronavirus disease 2019 patients requiring mechanical ventilation: a series of 21 consecutive cases. Crit Care Explor. 2020;2(6):e0145. https://​doi.​org/​10.​1097/​CCE.​0000000000000145​. CrossRef Hazbun ME, Faust AC, Ortegon AL, Sheperd LA, Weinstein GL, Doebele RL, Weinmeister KD, Liddell AM, Feldman M. The combination of tocilizumab and methylprednisolone along with initial lung recruitment strategy in coronavirus disease 2019 patients requiring mechanical ventilation: a series of 21 consecutive cases. Crit Care Explor. 2020;2(6):e0145. https://​doi.​org/​10.​1097/​CCE.​0000000000000145​. CrossRef
35.
Zurück zum Zitat Fatima SA, Asif M, Khan KA, Siddique N, Khan AZ. Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease. Ann Med Surg. 2020;60:413–6. CrossRef Fatima SA, Asif M, Khan KA, Siddique N, Khan AZ. Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease. Ann Med Surg. 2020;60:413–6. CrossRef
36.
Zurück zum Zitat Mora-Luján JM, Tuells M, Montero A, Formiga F, Homs NA, Albà-Albalate J, Corbella X, Rubio-Rivas M. High-dose methylprednisolone pulses for 3 days vs. low-dose dexamethasone for 10 days in severe, non-critical COVID-19: a retrospective propensity score matched analysis. J Clin Med. 2021;10(19):4465. CrossRef Mora-Luján JM, Tuells M, Montero A, Formiga F, Homs NA, Albà-Albalate J, Corbella X, Rubio-Rivas M. High-dose methylprednisolone pulses for 3 days vs. low-dose dexamethasone for 10 days in severe, non-critical COVID-19: a retrospective propensity score matched analysis. J Clin Med. 2021;10(19):4465. CrossRef
39.
Zurück zum Zitat Munch MW, Meyhoff TS, Helleberg M, Kjær MBN, Granholm A, Hjortsø CJS, Jensen TS, Møller MH, Hjortrup PB, Wetterslev M. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiol Scand. 2021;65(10):1421–1430. https://​doi.​org/​10.​1111/​aas.​13941. CrossRef Munch MW, Meyhoff TS, Helleberg M, Kjær MBN, Granholm A, Hjortsø CJS, Jensen TS, Møller MH, Hjortrup PB, Wetterslev M. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiol Scand. 2021;65(10):1421–1430. https://​doi.​org/​10.​1111/​aas.​13941. CrossRef
40.
Zurück zum Zitat Du Plessis E, Lalla U, Allwood B, Louw E, Nortje A, Parker A, Taljaard J, Ayele B, Nyasulu P, Koegelenberg C. Corticosteroids in critical COVID-19: Are all corticosteroids equal? South Afr Med J. 2021;111(6):550–3. Du Plessis E, Lalla U, Allwood B, Louw E, Nortje A, Parker A, Taljaard J, Ayele B, Nyasulu P, Koegelenberg C. Corticosteroids in critical COVID-19: Are all corticosteroids equal? South Afr Med J. 2021;111(6):550–3.
41.
Zurück zum Zitat Williams DM. Clinical pharmacology of corticosteroids. Respir Care. 2018;63(6):655–70. CrossRef Williams DM. Clinical pharmacology of corticosteroids. Respir Care. 2018;63(6):655–70. CrossRef
Metadaten
Titel
Comparison of the efficacy of equivalent doses of dexamethasone, methylprednisolone, and hydrocortisone for treatment of COVID-19-related acute respiratory distress syndrome: a prospective three-arm randomized clinical trial
verfasst von
Abbas Taher
Marjan Lashkari
Fariba Keramat
Seyyed Hamid Hashemi
Ladan Sedighi
Jalal Poorolajal
Associate Professor Maryam Mehrpooya
Publikationsdatum
09.01.2023
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-022-00993-4